Stay updated on Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial
Sign up to get notified when there's something new on the Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial page.

Latest updates to the Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to include a new multicenter phase II study evaluating the combination of denosumab and nivolumab for stage IV non-small-cell lung cancer patients with bone metastases, along with details about the study's inclusion and exclusion criteria. Additionally, the principal investigator's name has been added.SummaryDifference47%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 13, 2025.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check80 days agoChange DetectedThe page has been updated to reflect the current status of the DENIVOS study, including new dates and the removal of outdated information regarding its status and last updates.SummaryDifference3%
Stay in the know with updates to Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Denosumab+Nivolumab in Stage IV NSCLC Clinical Trial page.